Ipsen S.A./€IPN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ipsen S.A.
Ipsen S.A. is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. The company focuses on the development and commercialization of innovative medicines in targeted therapeutic areas such as oncology, neuroscience, and rare diseases. Ipsen's key products include Somatuline, a treatment for neuroendocrine tumors and acromegaly, and Dysport, used for movement disorders and aesthetic indications. Founded in 1929 by Henri Beaufour, Ipsen has since expanded its presence worldwide, with a strategic emphasis on specialty care and the development of differentiated products. The company leverages its scientific expertise and research capabilities to sustain its competitive position in the biopharmaceutical industry.
- Ticker
- €IPN
- Sector
- Health
- Primary listing
- PAR
- Employees
- 5,535
- Headquarters
- Paris, France
- Website
- www.ipsen.com
Ipsen S.A. Metrics
BasicAdvanced
€13B
24.80
€6.17
0.32
€1.60
1.05%
Price and volume
Market cap
€13B
Beta
0.32
52-week high
€176.00
52-week low
€116.50
Average daily volume
122K
Dividend rate
€1.60
Financial strength
Current ratio
1.965
Quick ratio
1.712
Long term debt to equity
0.133
Total debt to equity
0.163
Dividend payout ratio (TTM)
25.71%
Interest coverage (TTM)
22.24%
Profitability
EBITDA (TTM)
1,493.6
Gross margin (TTM)
81.01%
Net profit margin (TTM)
11.95%
Operating margin (TTM)
27.37%
Effective tax rate (TTM)
27.00%
Revenue per employee (TTM)
€780,000
Management effectiveness
Return on assets (TTM)
10.27%
Return on equity (TTM)
11.44%
Valuation
Price to earnings (TTM)
24.8
Price to revenue (TTM)
2.943
Price to book
2.68
Price to tangible book (TTM)
6.48
Price to free cash flow (TTM)
11.532
Free cash flow yield (TTM)
8.67%
Free cash flow per share (TTM)
13.267
Dividend yield (TTM)
1.05%
Forward dividend yield
1.05%
Growth
Revenue change (TTM)
14.14%
Earnings per share change (TTM)
14.85%
3-year revenue growth (CAGR)
9.35%
10-year revenue growth (CAGR)
10.54%
3-year earnings per share growth (CAGR)
4.45%
10-year earnings per share growth (CAGR)
8.16%
3-year dividend per share growth (CAGR)
10.06%
10-year dividend per share growth (CAGR)
6.53%
What the Analysts think about Ipsen S.A.
Analyst ratings (Buy, Hold, Sell) for Ipsen S.A. stock.
Analyst projections of the future price of Ipsen S.A. stock.
Bulls say / Bears say
H1 sales rose 23.5% at constant exchange rates and core operating income grew 28.8%, prompting Ipsen to raise its 2026 sales-growth and margin targets. This points to strong momentum across its existing portfolio, not just future pipeline hopes. (Ipsen)
Dysport met the primary endpoints in Phase III trials for both episodic and chronic migraine, giving Ipsen a potential new use for an established medicine. The results support planned regulatory submissions and could broaden its neuroscience franchise. (Ipsen)
Iqirvo’s Phase IIIb study found ALP levels normalised in 85% of treated patients, versus 23% on placebo, in a primary biliary cholangitis group with less elevated levels. If regulators accept the data, it could widen the medicine’s addressable patient population. (Ipsen)
The FDA approved a generic version of Somatuline earlier than expected, putting pressure on a medicine that accounted for about 31% of Ipsen’s first-half sales. This may erode a major revenue stream as generic supply returns. (The Wall Street Journal)
Bylvay failed to improve native-liver survival in its Phase III biliary-atresia trial. That removes a potential expansion opportunity for the drug, although its existing approved uses remain separate. (Ipsen)
Ipsen withdrew Tazverik from all markets after emerging safety data in a confirmatory trial raised concern about secondary blood cancers. The withdrawal removes the medicine from its portfolio and highlights the risk that safety findings can derail commercial products. (Ipsen)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
Ipsen S.A. Financial Performance
Revenues and expenses
Ipsen S.A. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Ipsen S.A.
AllEURUSDGBP
Fund name | Fund size | €IPN weighting |
|---|---|---|
iShares EURO STOXX Mid Cap£DJMC | €595M | 0.68% |
iShares EURO STOXX Mid€DJMC | €595M | 0.68% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.60% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.60% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.60% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.